Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility ...
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.